Alpine Immune Sciences logo

Alpine Immune Sciences

Seattle, WA

Alpine Immune Sciences, Inc. (AIS) focuses on developing novel protein-based cancer immunotherapies using its proprietary variant ig domain (vIgD) platform technology. The Company develops TIP technology, based on the vIgD platform, to enhance engineered cellular therapies. AIS offers a platform to interact with multiple targets, including many present in the immune synapse.

alpineimmunesciences.com

Company Details

Founded

2015

Employees

142 employees

Raised

$515,300,000

Headquarters Location

Seattle, WA

Public

Yes

Acquired

Yes

CEO

Mitchell GoldMitchell Gold

Founders

Ryan Swanson
Ryan Swanson
Michael Kornacker
Michael Kornacker
Mitchell Gold
Mitchell Gold

Company Collections

These are collections Alpine Immune Sciences is a part of. Click on the collection name to view similar companies.

Alpine Immune Sciences' Tech Stack

Alpine Immune Sciences' Investors

Alpine Immune Sciences Headquarters Location

188 E Blaine St suite 200, Seattle, WA 98102

Total Amount Raised: $515,300,000

Alpine Immune Sciences' Investors

Alpine Immune Sciences Funding Rounds

  • Post Ipo Equity

    $150,000,000

  • Post Ipo Equity

    $100,000,000

  • Post Ipo Equity

    $91,000,000

    Post Ipo Equity Investors

    Frazier Management
    Logos Capital
    BVF Partners
    OrbiMed Advisors
    Avidity Partners
    Decheng Capital
    Omega Fund Management
    TCG Crossover Management
  • Post Ipo Equity

    $60,000,000

    Post Ipo Equity Investors

    Omega Fund Management
    Avidity Partners
    EcoR1 Capital
    Samsara BioCapital
  • Post Ipo Equity

    $25,000,000

    Post Ipo Equity Investors

    Decheng Capital
    OrbiMed Advisors
    Frazier Management
    Alpine BioVentures GP
    BVF Partners
  • IPO

    Unknown

  • Series A

    $48,000,000

    Series A Investors

    OrbiMed Advisors
    Frazier Management
    Alpine BioVentures GP
  • Seed

    $1,300,000

  • Series Unknown

    $30,000,000

    Series Unknown Investors

    Wellington Management
    RA Capital Management
    Jennison Associates
    Rock Springs Capital
    Sabby Management
  • Series B

    $10,000,000

    Series B Investors

    Bridger Management
    Tiger Global Management
    Deerfield Management
Funding info provided by Diffbot.

Alpine Immune Sciences Reviews

0 out of 5 stars

Based on 0 reviews

Review data

Share your thoughts

Worked here? Share your experience. Help others decide if this company is right for them. Write a review on Alpine Immune Sciences.

Recent reviews